Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

IL-8 as a potential biomarker in Guillain-Barre Syndrome

IL-8 as a potential biomarker in Guillain-Barre Syndrome This pilot study was designed to compare the levels of interleukin-8 (IL-8), a pro-inflammatory chemokine, in the cerebrospinal fluid (CSF) of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), non-inflammatory polyneuropathy (PNP), and other non-inflammatory neurological diseases (functional syndrome or migraine). The results show elevated CSF IL-8 levels in GBS compared to the other groups (p < 0.05). IL-8 could be considered a potential biomarker to differentiate GBS from CIDP. This distinction could be relevant in terms of therapeutic decisions and functional prognosis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Cytokine Network Springer Journals

IL-8 as a potential biomarker in Guillain-Barre Syndrome

Loading next page...
 
/lp/springer-journals/il-8-as-a-potential-biomarker-in-guillain-barre-syndrome-HeI4aIaaOd
Publisher
Springer Journals
Copyright
Copyright © JLE/Springer 2019
eISSN
1952-4005
DOI
10.1684/ecn.2019.0436
Publisher site
See Article on Publisher Site

Abstract

This pilot study was designed to compare the levels of interleukin-8 (IL-8), a pro-inflammatory chemokine, in the cerebrospinal fluid (CSF) of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), non-inflammatory polyneuropathy (PNP), and other non-inflammatory neurological diseases (functional syndrome or migraine). The results show elevated CSF IL-8 levels in GBS compared to the other groups (p < 0.05). IL-8 could be considered a potential biomarker to differentiate GBS from CIDP. This distinction could be relevant in terms of therapeutic decisions and functional prognosis.

Journal

European Cytokine NetworkSpringer Journals

Published: Dec 2, 2019

There are no references for this article.